The Binding Site was set up by professor Jo Bradwell and researchers at Birmingham University to develop specialist blood-tests for diagnosing and monitoring bone marrow cancers and other immune system disorders . Under chief executive Charles de Rohan, sales grew 17% to £92m in 2016, partly as a result of the drop in the value of the pound. More than 90% of sales is generated abroad. Nordic Capital bought a majority stake in 2011 for an undiclosed sum.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.